Medicare's Foreign Price Bench-marking Will Only Hurt Bad Negotiators, HHS's Azar Argues
Executive Summary
President Trump touts CMS proposal that would peg Part B prices to an international index in the hopes of lowering US costs; industry calls it foreign price controls and warns it will hinder access.
You may also be interested in...
Former AAM Boss Leonard Moves To Brand Drug Industry-Backed We Work For Health
The 16-year-old WWFH is closely aligned with PhRMA and focuses on ‘bringing together national and local business leaders, labor, biopharma, patient advocacy and other healthcare-related stakeholders.’
Trump’s Drug Pricing Plan: The Headlines Are The Goal – But Also A Threat
The latest flurry of Executive Order activity on drug pricing reinforces the message that the President wants to own the headlines for being tough on the drug industry as Election Day looms. Looking for substance beyond that goal is a fool’s errand – but the headlines could still have significant consequences no matter who wins in November.
Trump’s Executive Order Limiting Medicare Drug Payments Faces Hurdles
Under test payment model, Medicare would pay no more than most-favored-nation price for Part B and Part D drugs, but how and when the model program would be implemented remains unclear. BIO may pursue legal action as questions on how plan would be implemented and if the administration will provide notice and comment period for stakeholder input remain.